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Coronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome 25 
coronavirus 2 (SARS-CoV-2) (13), has become an unprecedented public health crisis. 26 
Coronavirus Resource Center at Johns Hopkins University of Medicine has reported a 27 
total of 23,638 deaths as worldwide COVID-19 infections surpass 500,000 (as of 5pm 28 
EST on March 26, 2020). On March 16, 2020, the White House collaborating with 29 
research institutes and tech companies has issued a call to action for global artificial 30 
intelligence researchers for developing novel text and data mining techniques to assist 31 
COVID-19 related research. The Allen institute for AI in partnership with leading 32 
research groups issued an open-source, weekly updated COVID-19 Open Research 33 
Dataset (2), which continuously documents COVID-19 related scholar articles to 34 
accelerate novel research projects urgently requiring real-time data. The large-scale 35 
data of COVID-19 patients can be integrated and analyzed using advanced machine 36 
learning algorithms to better understand the pattern of viral spread, further improve 37 
diagnostic speed and accuracy, develop novel effective therapeutic approaches, and 38 
potentially identify the most susceptible people based on personalized genetic and 39 
physiological characteristics. Inspirationally, within a short period of time since COVID-40 
19 outbreak, advanced machine learning techniques have been used in taxonomic 41 
classification of COVID-19 genomes (8), CRISPR-based COVID-19 detection assay (6), 42 
survival prediction of severe COVID-19 patients (11), and discovering potential drug 43 
candidates against COVID-19 (4).  44 
 45 
Personalized protective strategies can greatly benefit from precise classifications of the 46 
population based on categorized COVID-19 susceptibility. The earlier observation that 47 
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elderly people have a higher risk to COVID-19 is challenged by a recent finding that 48 
more and more young adults suffer from severe COVID-19 symptoms, indicating an 49 
urgent need of a comprehensive risk evaluation based on personalized genetic and 50 
physiological characteristics. Human angiotensin-converting enzyme 2 (ACE2), 51 
expressed in epithelial cells of lung, small intestines, heart and kidneys, is an entry 52 
receptor for SARS-CoV-2 spike glycoprotein (3, 13). Fang et al. hypothesized that 53 
increased expression of ACE2, by using ACE2-stimulating drugs to treat hypertension 54 
and diabetes, could actually worsen clinical outcomes of COVID-19 infection (3). 55 
Indeed, this hypothesis should be further tested with strict experimental designs and 56 
long-term clinical observations. Therefore, biochemistry (e.g., ACE2 expression level) 57 
and clinical data (e.g., age, respiratory pattern, viral load and survival) of COVID-19 58 
patients with underlying medical conditions can be analyzed using machine learning 59 
approaches to not only identify any reliable features (e.g., ACE2) for risk prediction, but 60 
also further perform risk classification and prediction for a balanced preparation of 61 
ongoing disease treatment and COVID-19 defense (Figure 1). ACE2 genetic 62 
polymorphism, represented by diverse genetic variants in human genome, has been 63 
shown to affect virus-binding activity (1), suggesting a possible genetic predisposition to 64 
COVID-19 infection. Therefore, machine learning analysis of genetic variants from 65 
asymptomatic, mild or severe COVID-19 patients can be performed to classify and 66 
predict people based on their vulnerability or resistance to potential COVID-19 infection, 67 
by which the machine learning model can also return those prioritized genetic variants, 68 
such as ACE2 polymorphism, in their decision-making process as important features for 69 
functional and mechanistic studies (Figure 1).  70 





Figure 1. Application of artificial intelligence and machine learning in the fight against 74 
COVID-19. 75 
 76 
Currently, ongoing efforts have been made to develop novel diagnostic approaches 77 
using machine learning algorithms. For example, machine learning based screening of 78 
SARS-CoV-2 assay designs using a CRISPR-based virus detection system was 79 
demonstrated with high sensitivity and speed (6). Neural network classifiers were 80 
developed for a large-scale screening of COVID-19 patients based on their distinct 81 
respiratory pattern (10). Similarly, a deep-learning based analysis system of thoracic CT 82 
images was constructed for automated detection and monitoring of COVID-19 patients 83 
over time (5). Rapid development of automated diagnostic systems based on artificial 84 
intelligence and machine learning can not only contribute to increased diagnostic 85 
accuracy and speed, but will also protect healthcare workers by decreasing their 86 
contacts with COVID-19 patients (Figure 1).  87 
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 88 
An effective therapeutic strategy is urgently needed to treat rapidly growing COVID-19 89 
patients worldwide.  As there is no effective drug proven to treat COVID-19 patients, it is 90 
critical to develop efficient approaches to repurpose clinically-approved drugs or design 91 
new drugs against SARS-CoV-2. A machine learning based repositioning and 92 
repurposing framework was developed to prioritize existing drug candidates against 93 
SARS-CoV-2 for clinical trials (4). Additionally, a deep learning based drug discovery 94 
pipeline has been used to design and generate novel drug-like compounds against 95 
SARS-CoV-2 (12). AlphaFold (9), which is a deep learning system developed by Google 96 
DeepMind, has released predicted protein structures associated with COVID-19, which 97 
can take months using traditional experimental approaches, serving as valuable 98 
information for COVID-19 vaccine formula. Moreover, COVID-19 vaccine candidates 99 
were proposed by a newly developed Vaxign reverse vaccinology tool integrated with 100 
machine learning (7). The tremendous amount of COVID-19 treatment data in 101 
worldwide hospitals also require advanced machine learning methods for analyzing 102 
personalized therapeutic effects for evaluating new patients, such as hospitalization 103 
prediction, which can not only provide better care for each patient but also contribute to 104 
local hospital arrangement and operation (Figure 1). 105 
 106 
As artificial intelligence and machine learning scientists have been eagerly searching 107 
and waiting for real-time data generated by this pandemic around the world, timely 108 
delivery of COVID-19 patient data, such as physiological characteristics and therapeutic 109 
outcome of COVID-19 patients, followed by subsequent data transformation for easy 110 
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access, is extremely important, but challenging. Figure 1 is a schematic representation 111 
of the workflow, but there are several steps in the process that currently limit the 112 
application of machine learning and artificial intelligence to combat COVID-19. 113 
Availability of COVID-19 related clinical data, which can be managed and processed 114 
into easily accessible databases is a key current barrier. Thereby, development of 115 
cyber-infrastructure to fuel world-wide collaborations is important.  To this end, the US 116 
federal agencies are already promoting the formations of consortia and funding 117 
opportunities (https://www.nsf.gov/pubs/2020/nsf20055/nsf20055.jsp).  In addition to 118 
these initiatives, Integrating COVID-19 related clinical data with existing biobanks, such 119 
as the UK Biobank, with pre-existing data of those patients (if already in biobanks), such 120 
as their genotype and physiological characteristics, could maximize our efforts towards 121 
a faster, feasible means to the end of meaningful data-mining by bioinformaticians and 122 
computational scientists. A centralized collection of worldwide COVID-19 patient data 123 
will be beneficial for future artificial learning and machine learning research to develop 124 
predictive, diagnostic and therapeutic strategies against COVID-19 and similar 125 
pandemics in future. 126 
 127 
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